Ken Cacciatore
Stock Analyst at TD Cowen
(0.31)
# 4,129
Out of 4,868 analysts
13
Total ratings
27.27%
Success rate
-28.39%
Average return
Main Sectors:
Stocks Rated by Ken Cacciatore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $65 → $50 | $13.26 | +277.07% | 2 | Aug 9, 2023 | |
| BHC Bausch Health Companies | Downgrades: Market Perform | n/a | $5.73 | - | 1 | Jun 16, 2023 | |
| TAK Takeda Pharmaceutical Company | Maintains: Outperform | $30 → $20 | $14.89 | +34.32% | 4 | May 16, 2023 | |
| SCPH scPharmaceuticals | Initiates: Outperform | $25 | $3.99 | +526.57% | 1 | Dec 1, 2022 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $35 | $11.58 | +202.25% | 1 | May 11, 2022 | |
| MOLN Molecular Partners AG | Initiates: Outperform | $50 | $3.76 | +1,229.79% | 1 | Jul 13, 2021 | |
| TARA Protara Therapeutics | Initiates: Outperform | $50 | $3.06 | +1,533.99% | 1 | Oct 19, 2020 | |
| BHVN Biohaven | Initiates: Outperform | $45 | $14.56 | +209.07% | 1 | Apr 17, 2020 | |
| AMRN Amarin Corporation | Initiates: Outperform | $460 | $13.31 | +3,357.35% | 1 | Mar 2, 2020 |
Arcutis Biotherapeutics
Aug 9, 2023
Maintains: Outperform
Price Target: $65 → $50
Current: $13.26
Upside: +277.07%
Bausch Health Companies
Jun 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $5.73
Upside: -
Takeda Pharmaceutical Company
May 16, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $14.89
Upside: +34.32%
scPharmaceuticals
Dec 1, 2022
Initiates: Outperform
Price Target: $25
Current: $3.99
Upside: +526.57%
Bausch + Lomb
May 11, 2022
Initiates: Outperform
Price Target: $35
Current: $11.58
Upside: +202.25%
Molecular Partners AG
Jul 13, 2021
Initiates: Outperform
Price Target: $50
Current: $3.76
Upside: +1,229.79%
Protara Therapeutics
Oct 19, 2020
Initiates: Outperform
Price Target: $50
Current: $3.06
Upside: +1,533.99%
Biohaven
Apr 17, 2020
Initiates: Outperform
Price Target: $45
Current: $14.56
Upside: +209.07%
Amarin Corporation
Mar 2, 2020
Initiates: Outperform
Price Target: $460
Current: $13.31
Upside: +3,357.35%